Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and HealthEquity (HQY). But which of these two stocks offers value investors a better ba
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
B. Metzler seel. Sohn and Co. AG cut its stake in shares of Solventum Corporation (NYSE: SOLV) by 68.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Ex
SBC Medical Group (NASDAQ: SBC - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based
The consensus price target hints at a 26.3% upside potential for Solventum (SOLV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SOLV rides on strong segment demand, innovation push and cost savings plan, but tariffs and rising input costs cloud margin outlook.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Solventum (SOLV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SOLV broke out above the 50-day moving average, suggesting a
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

SOLV Energy: Valuation Too Low Vs. Peers

10:45am, Wednesday, 15'th Apr 2026
SOLV Energy is undervalued, with a recurring O&M revenue stream and a robust $8B backlog supporting near-term growth. MWH's installed base and long-term O&M contracts create a higher-quality, stickier
ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close.
Solventum (SOLV) is rated Very Unattractive due to negative economic earnings, low ROIC (5%), and an expensive valuation. Street Earnings and significantly overstate SOLV's true profitability; Core Ea
Investors looking for stocks in the Medical Services sector might want to consider either Solventum (SOLV) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE